The first half of 2022 is behind us and for most in the industry, it was a six month period to forget. Have we hit the bottom, or will we plummet still further in the second half of the year? This eBook digs into the business side of the biotech, pharma and medtech markets to […]
Share:
The first half of 2022 is behind us and for most in the industry, it was a six month period to forget. Have we hit the bottom, or will we plummet still further in the second half of the year?
This eBook digs into the business side of the biotech, pharma and medtech markets to look hard for any glimmers of hope to sustain us as we crack on with the remainder of the year.
Western pharma committed close to $2 billion in licensing deals and acquisitions for China-originated assets in Q1 2026 alone.
